Clinical Trials

Carcinoma, Hepatocellular

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07455617 2026-04-06

Study of ABO2102 in KRAS-Mutated Solid Tumors

Phase 1 Recruiting

101 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04512534 2026-04-02

Sincerely20

51 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular

NCT05427487 2026-03-25

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Phase 1 Recruiting

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07492342 2026-03-25

K-NADIR

Thoracic

Resectable NSCLC

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT06497985 2026-03-19

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

430 enrolled

Colorectal Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

39 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

49 enrolled

Rectal Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

280 enrolled

Carcinoma, Hepatocellular

NCT06353646 2026-02-13

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Phase NA Recruiting

28 enrolled

Pancreatic Neoplasms

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Colorectal Neoplasms

NCT07371611 2026-01-28

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

104 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07120698 2026-01-05

CTONG 2508

115 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT06121505 2025-12-17

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

114 enrolled

Lung Squamous Cell Carcinoma

NCT07263386 2025-12-04

ARTEMIS-GC3

460 enrolled

Gastric Adenocarcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07194005 2025-09-26

Remission

Stomach Neoplasms

NCT07186621 2025-09-22

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

286 enrolled

Carcinoma, Hepatocellular

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

35 enrolled

Rectal Neoplasms

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06031285 2025-07-23

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

43 enrolled

Carcinoma, Hepatocellular

NCT06050317 2025-07-22

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreatic Neoplasms

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

70 enrolled

Metastatic Gastroesophageal Junction Adenocarcinoma

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT07025889 2025-06-18

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

55 enrolled

Stomach Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

CNS

Neuroblastoma

NCT05357846 2025-06-12

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

422 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06794086 2025-05-13

SPARKLE-L

24 enrolled

Colorectal Neoplasms

NCT06956716 2025-05-04

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

NCT06925243 2025-04-22

Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

682 enrolled

Stomach Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT06860490 2025-03-26

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

164 enrolled

Carcinoma, Hepatocellular

NCT05165407 2025-03-14

NESSIE

EndocrineNET

Neuroendocrine Tumors

NCT06698757 2025-03-13

Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer

96 enrolled

Colorectal Neoplasms

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Cholangiocarcinoma

NCT05057052 2025-02-27

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Liver Metastases

NCT05098847 2025-02-27

Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors

Liver Metastasis

NCT06494943 2025-02-25

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

27 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06841159 2025-02-24

iPULSAR-CRC

116 enrolled